Fredun Pharmaceuticals (539730) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
6 Jun, 2025Executive summary
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion on both.
Final dividend of 7% per equity share (₹0.70 per ₹10 share) recommended, subject to AGM approval.
Group expanded with the incorporation of Fredun Retail Private Limited and acquisition of One Pet Stop Private Limited, both consolidated for the first time.
Financial highlights
Standalone revenue for FY25: ₹45,626.82 lakh, up from ₹34,907.18 lakh in FY24.
Standalone net profit for FY25: ₹2,080.76 lakh, up from ₹1,562.34 lakh in FY24.
Consolidated revenue for FY25: ₹45,626.85 lakh; consolidated net profit: ₹1,973.93 lakh.
Q4 FY25 standalone net profit: ₹707.18 lakh, up from ₹533.26 lakh in Q4 FY24.
EPS (standalone, FY25): ₹44.83 vs. ₹33.32 in FY24; consolidated EPS: ₹44.83.
Outlook and guidance
Board recommended a final dividend of 7% per equity share, subject to shareholder approval at the AGM.
Latest events from Fredun Pharmaceuticals
- Revenue and profit soared with strong growth, margin gains, and robust compliance in key segments.539730
Q1 26/27 - Strong revenue and profit growth, margin expansion, 2:1 bonus issue, and final dividend.539730Q4 25/26
- Strong revenue and profit growth, margin expansion, and stable capital structure.539730Q3 25/26
- Double-digit revenue and profit growth, improved margins, and positive cash flow in H1 FY26.539730Q2 25/26
- Revenue and profit soared year-on-year, with robust new age business and board expansion.539730Q1 25/26
- Q2 FY25 saw revenue and profit growth, but cash flow and liquidity pressures increased.539730Q2 24/25
- Q1 FY25 saw strong revenue and profit growth, with EPS rising to ₹8.79.539730Q1 24/25
- Revenue and profit increased, and a new retail subsidiary was established.539730Q3 24/25